2BO.F Serina Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
1.23 EUR
Close of Nov 11, 2026
1.07 4.00
Market cap
EUR 31.2M
P/E
-
P/B
1.86x
ROE
-141.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2BO.F undervalued?

Graham number

The Graham number of Serina Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Serina Therapeutics, Inc. fundamental analysis

No fundamental analysis for Serina Therapeutics, Inc. yet.

Serina Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Serina Therapeutics, Inc.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg …

Full company profile